Compare WRBY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | PTGX |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 5.4B |
| IPO Year | 2021 | 2016 |
| Metric | WRBY | PTGX |
|---|---|---|
| Price | $26.45 | $85.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $25.43 | ★ $90.56 |
| AVG Volume (30 Days) | ★ 5.7M | 1.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.00 | ★ 0.72 |
| Revenue | ★ $850,580,000.00 | $209,217,000.00 |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $12.84 | $296.47 |
| P/E Ratio | $4,496.42 | ★ $119.48 |
| Revenue Growth | ★ 14.55 | N/A |
| 52 Week Low | $13.63 | $33.70 |
| 52 Week High | $31.00 | $96.54 |
| Indicator | WRBY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 47.49 |
| Support Level | $25.78 | $84.11 |
| Resistance Level | $27.96 | $96.54 |
| Average True Range (ATR) | 2.01 | 3.32 |
| MACD | 0.50 | -0.87 |
| Stochastic Oscillator | 65.45 | 18.55 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.